ArticleNucleic acids research2011
An integrated transcriptomic and computational analysis for biomarker identification in gastric cancer.
Article in Nucleic acids research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 136 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
136 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-Analysis of Public Microarray Datasets Reveals Voltage-Gated Calcium Gene Signatures in Clinical Cancer Patients.PloS one · 2015Pooled it
- FMRP promotes gastric cancer progression via mJournal of translational medicine · 2026Article
- Oncolytic vaccinia virus JX-594 shows subtype-specific activity and candidate biomarkers in gastric cancer cell lines.Scientific reports · 2026Article
- Article
- Advances in protein microarray-based proteomics for gastric cancer applications in biomarker discovery, molecular subtyping, and precision oncology.Frontiers in oncology · 2026Review
- Machine learning identifies INHBA DPT ADH7 FBP2 and GPR155 as diagnostic biomarkers for gastric cancer.Discover oncology · 2025Article
- SENP1 drives glycolysis and cisplatin resistance in gastric cancer via desumoylating ENO1.Journal of experimental & clinical cancer research : CR · 2025Article
- Pan‑cancer analysis of oncogene SFXN1 to identify its prognostic and immunological roles in lung adenocarcinoma.Oncology reports · 2025Article
- Network-based multi-omics integrative analysis methods in drug discovery: a systematic review.BioData mining · 2025Review
- Identification and validation of tumor microenvironment-related therapeutic targets in gastric cancer using integrated multi-omics and molecular docking approaches.Frontiers in bioinformatics · 2025Article
- Identification and validation of CCN family genes to predict the prognosis in gastric cancer.Discover oncology · 2024Article
- FASTKD1 as a diagnostic and prognostic biomarker for STAD: Insights into m6A modification and immune infiltration.Experimental and therapeutic medicine · 2024Article
- MicroRNAs in Pancreatic Cancer: Advances in Biomarker Discovery and Therapeutic Implications.International journal of molecular sciences · 2024Review
- Chromatin Remodeling-Related PRDM1 Increases Stomach Cancer Proliferation and Is Counteracted by Bromodomain Inhibitor.Journal of personalized medicine · 2024Article
- ESM1 facilitates the EGFR/HER3-triggered epithelial-to-mesenchymal transition and progression of gastric cancer via modulating interplay between Akt and angiopoietin-2 signaling.International journal of biological sciences · 2024Article
- Identification of INHBA as a potential biomarker for gastric cancer through a comprehensive analysis.Scientific reports · 2023Article
- Identification of a potential competing endogenous RNA (ceRNA) network in gastric adenocarcinoma.Journal of gastrointestinal oncology · 2023Article
- Targeting integrin α2 as potential strategy for radiochemosensitization of glioblastoma.Neuro-oncology · 2023Article
- AFAP1L1 promotes gastric cancer progression by interacting with VAV2 to facilitate CDC42-mediated activation of ITGA5 signaling pathway.Journal of translational medicine · 2023Article
- Is NAD(P)H quinone oxidoreductase 1 a tumor promoter or suppressor in gastric cancer?Frontiers in oncology · 2023Article
76 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
This report describes an integrated study on identification of potential markers for gastric cancer in patients' cancer tissues and sera based on: (i) genome-scale transcriptomic analyses of 80 paired gastric cancer/reference tissues and (ii) computational prediction of blood-secretory proteins supported by experimental validation. Our findings show that: (i) 715 and 150 genes exhibit significantly differential expressions in all cancers and early-stage cancers versus reference tissues, respectively; and a substantial percentage of the alteration is found to be influenced by age and/or by gender; (ii) 21 co-expressed gene clusters have been identified, some of which are specific to certain subtypes or stages of the cancer; (iii) the top-ranked gene signatures give better than 94% classification accuracy between cancer and the reference tissues, some of which are gender-specific; and (iv) 136 of the differentially expressed genes were predicted to have their proteins secreted into blood, 81 of which were detected experimentally in the sera of 13 validation samples and 29 found to have differential abundances in the sera of cancer patients versus controls. Overall, the novel information obtained in this study has led to identification of promising diagnostic markers for gastric cancer and can benefit further analyses of the key (early) abnormalities during its development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.